Portable all-in-one microfluidic system for CRISPR-Cas13a-based fully integrated multiplexed nucleic acid detection

Rapid identification of communicable pathogens remains a cornerstone of global public health infrastructure and pandemic preparedness. Prior research has shown that existing molecular diagnostics often rely on centralized laboratory equipment that limits accessibility in resource-constrained environments. Traditional Polymerase Chain Reaction (PCR) workflows necessitate complex thermal cycling and specialized technical expertise that are unavailable in field settings. While microfluidic platforms offer potential for miniaturization, many current designs lack full integration of extraction and amplification steps. Existing systems frequently require multiple manual interventions, increasing the risk of contamination and human error during sample handling. These technological constraints prevent the widespread adoption of point-of-care testing for emerging viral threats. This absence of evidence motivated the development of a truly autonomous platform capable of processing raw samples without external machinery.

This research engineers a portable centrifugal microfluidic testing system to achieve fully integrated 'sample-in, answer-out' diagnostics for infectious diseases. The investigators sought to combine magnetic bead-based nucleic acid extraction with Recombinase-Assisted Amplification (RAA) and CRISPR-Cas13a detection on a single disc. Creating a programmable flow control mechanism using addressable active thermally-triggered wax valves served as a primary engineering objective for fluidic management. The team aimed to reduce total turnaround time to under 45 minutes while maintaining high analytical sensitivity across multiple targets. Establishing a multichannel architecture allowed for the simultaneous identification of ten distinct infectious viruses within a single diagnostic run. Validation across diverse matrices like plasma, nasopharyngeal swabs, and whole blood ensured the device's broad clinical utility in various healthcare scenarios. The project focused on creating a user-friendly interface requiring only one manual step to initiate the entire molecular analysis.

The platform utilizes a power-supplied active rotating chip to drive centrifugal fluid movement across various processing chambers designed for specific biochemical reactions. Reagents required for the assay are preloaded into the microfluidic architecture and released via automated thermal activation of addressable wax-based barriers. Nucleic acid isolation occurs through a magnetic bead-based extraction process integrated directly onto the rotating disc to ensure high purity of genetic material. Following extraction, the system performs isothermal Recombinase-Assisted Amplification (RAA) to increase target genetic material concentrations without the need for thermal cyclers. Detection relies on the collateral cleavage activity of the CRISPR-Cas13a enzyme, which generates a fluorescent signal upon specific target recognition. Analytical performance was benchmarked using plasmid samples and mock plasma to determine the precise Limit of Detection (LoD) for each viral target. Comparative analysis against standard laboratory-based molecular testing provided a rigorous assessment of clinical diagnostic accuracy using patient-derived specimens.

The integrated system successfully identified ten infectious viruses simultaneously with a total processing time of 45 minutes from sample introduction. Analytical sensitivity reached a Limit of Detection (LoD) of 1 copy per reaction in purified plasmid samples, demonstrating exceptional molecular precision. Testing within mock plasma environments demonstrated a robust Limit of Detection (LoD) of 5 copies per reaction, confirming the system's resilience to biological interference. Clinical plasma sample analysis showed high consistency with results obtained from conventional laboratory molecular diagnostics, validating the platform's diagnostic reliability. The device maintained high performance when processing complex matrices including nasopharyngeal swabs and whole blood, proving its versatility for different sampling methods. Automated reagent release and programmable flow control through wax valves eliminated the need for professional technicians during the testing process. These findings indicate that the centrifugal microfluidic approach provides laboratory-grade results in a portable, field-deployable format.

This portable microfluidic platform represents a significant advancement in decentralized molecular diagnostics for communicable diseases in resource-limited settings. The integration of CRISPR-Cas13a chemistry with centrifugal automation provides a scalable solution for on-site pathogen surveillance and rapid clinical decision-making. Eliminating the requirement for centralized laboratory equipment facilitates rapid response during infectious disease outbreaks where time-sensitive data is paramount. Future applications could extend this technology to a wider array of pathogens in diverse environmental or clinical settings beyond viral detection. The system's ease of use suggests it could be deployed in rural clinics or mobile units without extensive laboratory training. High sensitivity and multiplexing capabilities ensure that diagnostic accuracy is not sacrificed for the benefits of portability and speed. This innovation bridges the gap between sophisticated molecular biology and practical, accessible healthcare tools for global health security.